{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:00:39Z","timestamp":1760148039681,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin\u2019s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome associated with BV therapy. We present the case of a 64-year-old female, diagnosed with relapsed Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), who, after receiving six cycles of BV, developed authentic severe autoimmune hemolytic anemia with strong positive direct anti-globulin (Coombs) test, simultaneously associated with severe immune thrombocytopenia. The patient was unresponsive to systemic corticotherapy, but fully recovered after a course of IV immunoglobulin.<\/jats:p>","DOI":"10.3390\/hematolrep15010023","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T08:36:16Z","timestamp":1679474176000},"page":"220-224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Ruxandra","family":"Irimia","sequence":"first","affiliation":[{"name":"School of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 4192910 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 4192910 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinziana","family":"Barbu","sequence":"additional","affiliation":[{"name":"School of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 4192910 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 4192910 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Codruta","family":"Popa","sequence":"additional","affiliation":[{"name":"School of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 4192910 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 4192910 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorina","family":"Badelita","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 4192910 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/10428190701385173","article-title":"Autoimmune hemolytic anemias, Evans\u2019 syndromes, and pure red cell aplasia in non-Hodgkin lymphomas","volume":"48","author":"Hauswirth","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S176144","article-title":"Evans syndrome: Clinical perspectives, biological insights and treatment modalities","volume":"9","author":"Elva","year":"2018","journal-title":"J. Blood Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Audia, S., Grienay, N., Mounier, M., Michel, M., and Bonnotte, B. (2020). Evans\u2019 Syndrome: From Diagnosis to Treatment. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123851"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bjhh.2015.03.002","article-title":"Experience with Evans syndrome in an academic referral center","volume":"37","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1179\/102453308X343518","article-title":"Evans syndrome: A study of six cases with review of literature","volume":"13","author":"Jain","year":"2008","journal-title":"Hematology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood.2021012924","article-title":"T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome","volume":"139","author":"Kumar","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3329\/jom.v11i1.4280","article-title":"Evans syndrome","volume":"11","author":"Kabir","year":"2010","journal-title":"J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","article-title":"Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: The French named patient program experience in 56 patients","volume":"101","author":"Lamarque","year":"2016","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-020-00561-w","article-title":"Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma","volume":"15","author":"Shea","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2019-126787","article-title":"Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II\u2013IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085","volume":"134","author":"Rubinstein","year":"2019","journal-title":"Blood"},{"key":"ref_12","unstructured":"(2020, December 20). Adcetris (Brentuximab Vedotin) FDA Approval History\u2013Drugs.com. Available online: https:\/\/www.drugs.com\/history\/adcetris.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2009-04-215368","article-title":"The spectrum of Evans syndrome in adults: New insight into the disease based on the analysis of 68 cases","volume":"114","author":"Michel","year":"2009","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ajh.25574","article-title":"Evans syndrome in adults\u2013incidence, prevalence, and survival in a nationwide cohort","volume":"94","author":"Hansen","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bjh.15801","article-title":"Immune off-target effects of Brentuximab Vedotin in relapsed\/refractory Hodgkin Lymphoma","volume":"185","author":"Romano","year":"2019","journal-title":"Br. J. Haematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/1\/23\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:00:43Z","timestamp":1760122843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/1\/23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["hematolrep15010023"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15010023","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}